Marinkovic Milos, Nesic Jelena, Petrovic Ivica, Jovanovic Ivan P, Sekulic Marija, Djukic Svetlana, Djukic Aleksandar
University Clinical Center Kragujevac, Serbia.
University of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine, Kragujevac, Serbia.
J Appl Biomed. 2024 Dec;22(4):208-213. doi: 10.32725/jab.2024.022. Epub 2024 Nov 20.
Metabolic syndrome is a significant pro-inflammatory and pro-coagulant condition. The clinical association of adiponectin, a mainly antidiabetogenic molecule, and its interaction with platelets and platelet indices remains insufficiently investigated.
The aim of our study was to investigate the association of adiponectin with platelets and platelet indices in patients with metabolic syndrome.
The investigation was conducted as a cross-sectional study involving 113 subjects: 63 patients with the diagnosis of metabolic syndrome, and 50 healthy controls - with clear inclusion and exclusion criteria. The group of patients with metabolic syndrome was divided into two subgroups according to the platelet/high-density lipoprotein (HDL) ratio.
The subgroup with a higher platelet/HDL ratio was prediabetic. In the same subgroup of patients, a positive correlation between the adiponectin and mean platelet volume (MPV) was seen, while linear regression (95% CI) confirmed the association.
Considering that MPV is the index that indicates average platelet volume and activity, we believe this association with adiponectin can represent a protective compensatory response in patients with metabolic syndrome and prediabetes. Our results provide a basis for a more precise selection of patients in whom the future therapeutic application of recombinant adiponectin would be most effective.
代谢综合征是一种显著的促炎和促凝状态。脂联素是一种主要具有抗糖尿病作用的分子，其与血小板及血小板指标的临床关联尚未得到充分研究。
我们研究的目的是调查代谢综合征患者中脂联素与血小板及血小板指标之间的关联。
该调查作为一项横断面研究进行，涉及113名受试者：63名诊断为代谢综合征的患者和50名健康对照者——有明确的纳入和排除标准。代谢综合征患者组根据血小板/高密度脂蛋白（HDL）比值分为两个亚组。
血小板/HDL比值较高的亚组处于糖尿病前期。在同一亚组患者中，脂联素与平均血小板体积（MPV）之间呈正相关，线性回归（95%CI）证实了这种关联。
鉴于MPV是表明平均血小板体积和活性的指标，我们认为这种与脂联素的关联可能代表代谢综合征和糖尿病前期患者的一种保护性代偿反应。我们的结果为更精确地选择未来重组脂联素治疗应用最有效的患者提供了依据。
